Marketed and Late Stage Pipeline

MARKETED AND LATE STAGE

HEMATOLOGIC MALIGNANCIES SOLID TUMORS

BRENTUXIMAB VEDOTIN1* IXAZOMIB* PONATINIB2* BRIGATINIB* CABOZANTINIB3* NIRAPARIB4* The oncology field continues to evolve rapidly CD30 Monoclonal Antibody Drug Conjugate Proteasome Inhibitor BCR-ABL Inhibitor Anaplastic Lymphoma Kinase Inhibitor VEGFR/RTK Inhibitor PARP 1/2 Inhibitor Peripheral T-Cell Lymphoma Multiple Myeloma Philadelphia Chromosome Positive Acute ALK+ Non-Small Cell Lung Cancer Renal Cell Carcinoma, Hepatocellular Carcinoma, Ovarian Cancer, Prostate Cancer in areas of cancer biology and in harnessing Lymphoblastic Leukemia, Chronic Myeloid Leukemia Non-Small Cell Lung Cancer, Prostate Cancer immune biology for next generation therapies. PEVONEDISTAT RELUGOLIX5* MOBOCERTINIB We are prioritizing our emerging pipeline efforts NEDD8-Activating Enzyme Inhibitor Higher-Risk Myelodysplastic Syndromes, GnRH Antaganoist EGFR/HER2 Inhibitor Higher-Risk Chronic Myelomonocytic Leukemia, Prostate Cancer Non-Small Cell Lung Cancer with EGFR in the pursuit of curative therapies, with a focus on Low-Blast Acute Myelogenous Leukemia Exon 20 Insertion Mutation novel mechanisms in the cancer-immunity cycle. PIPELINE

NEXT-GEN INNATE AND CHECKPOINT MODULATORS CELL THERAPY HEMATOLOGIC SOLID MALIGNANCIES TUMORS TAK-981 TAK-676 TAK-6059 TAK-0076 TAK-94011 TAK-1027 SUMO Activating Enzyme Inhibitor STING Agonist Oncolytic Virus CD19 CAR-NK CD19 1XX CAR-T GPC3 CAR-T Solid Tumors, Hematologic Malignancies Solid Tumors Solid Tumors Relapsed/Refractory B-Cell Malignancies Relapsed/Refractory B-Cell Malignancies Solid Tumors

TAK-2528 TAK-573 TAK-18610 Agonist Redirected Checkpoint CD38 Attenukine Conditional EGFR-targeting T-cell Engager Fusion Protein PD1/OX40L Solid Tumors, Multiple Myeloma Solid Tumors Solid Tumors, Lymphomas

All programs have Global Development Rights unless otherwise noted.

1 Brentuximab vedotin is co-developed by Takeda and SeaGen 2 Takeda shares development rights with Incyte Corp. (Europe, Turkey and Israel) and Otsuka Pharm. (Asia Pacific territories). 3 Japan Only. In partnership with Exelixis, Inc. 4 Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea,Taiwan, Russia and Australia. 5 Japan and Asian countries. In partnership with Myovant Sciences, Inc. 6 Under licensing agreement and in collaboration with MD Anderson Cancer Center. 7 Collaboration with Noile-Immune Biotech. 8 Takeda retains an option to develop UNLESS OTHERWISE NOTED, ALL PRODUCTS ARE INVESTIGATIONAL IN THE SETTING IN WHICH THEY ARE CURRENTLY BEING STUDIED TAK-252 / SL-279252 with Shattuck Labs. 9 In Collaboration with Turnstone Biologics. 10 Takeda shares development rights for TAK-186 with Maverick Pharma Pvt. Ltd. 11 In Collaboration with Memorial Sloan Kettering Cancer Center. AND NOT APPROVED FOR THESE INDICATIONS, SAFETY AND EFFICACY NOT YET ESTABLISHED (SEE CLINICALTRIALS.GOV). VV-MEDMAT-42816 05/2021 *MARKETED PRODUCTS HAVE RECEIVED APPROVAL IN ONE OR MORE JURISDICTIONS Reference: https://www.clinicaltrials.gov (last accessed May, 2021)